According to a new Pharmaceutical Research and Manufacturers of America (PhRMA) report, U.S. biopharmaceutical companies have 215 medicines under development for the treatment of heart disease and stroke. The medicines, which are currently either in human clinical trials or undergoing U.S. Food and Drug Administration review, aim to treat or prevent these two leading causes of death in the United States by addressing heart failure, lipid disorders, stroke, and hypertension. PhRMA President and CEO John Castellani noted that many of these pipeline drugs use cutting-edge technologies including gene therapy and genetic engineering. He said, “These promising new approaches offer great hope to better prevent and treat heart diseases. They also hold the potential of helping to control costs within our healthcare system, as reflected in a growing body of evidence showing that medicines— including those for heart disease—can help control overall healthcare costs.” See PhRMA Press Release, June 12, 2013.